Bousquet J, Lund V J, van Cauwenberge P, Bremard-Oury C, Mounedji N, Stevens M T, El-Akkad T
Service des Maladies Respiratoires, Hôpital Arnaud de Villeneuve, Montpellier, France.
Allergy. 2003 Aug;58(8):733-41. doi: 10.1034/j.1398-9995.2003.00076.x.
Allergic rhinitis is a common disease altering quality of life. Its treatment is well established and guidelines have been proposed. However, their efficacy has never been tested. The aim of the study was to validate the guidelines of the International Consensus on Rhinitis in the treatment of seasonal allergic rhinitis.
A multicenter, multinational, open label, parallel, randomized study compared two therapeutic strategies in seasonal allergic rhinitis during a 3-week treatment. General practitioners were randomized into two groups. In the first group of 224 patients, doctors followed guidelines from the International Consensus on Rhinitis. Depending on the severity of nasal and ocular symptoms defined using visual analogue scales, patients received ebastine (an oral antihistamine), triamcinolone acetonide (a topical corticosteroid) and/or ophthalmic nedocromil sodium (a topical ocular cromone). In the second group of 241 patients, general practitioners had a free choice of treatment. The primary efficacy end points were quality of life measured using the standardized rhinoconjunctivitis quality of life questionnaire (RQLQ) and the symptom-medication scores assessed daily with an electronic dairy system.
Adjusted mean total symptom scores over 21 days were 4.93 in the guidelines strategy group compared with 7.48 in the free-choice treatment group (P = 0.0001). Mean total scores in the RQLQ decreased by 2.19 in the guidelines group compared with a decrease of 1.79 in the free-choice treatment group (P = 0.0001). At 21 days, the least square mean difference in improvement in overall scores for RQLQ in the guidelines group compared with the free-choice treatment group was 0.53, which was greater than the minimal important difference.
Patients with seasonal allergic rhinitis often present severe symptoms which are not well recognized or controlled by physicians using their own criteria of severity and treatment. Using a simple method for the evaluation of the severity and a simple therapeutic scheme based on International Guidelines, patients with seasonal allergic rhinitis presented a significant improvement by comparison with those receiving a non-standardized treatment.
变应性鼻炎是一种影响生活质量的常见疾病。其治疗方法已确立并已提出相关指南。然而,这些指南的疗效从未得到检验。本研究的目的是验证《鼻炎国际共识》指南在季节性变应性鼻炎治疗中的有效性。
一项多中心、跨国、开放标签、平行、随机研究在3周治疗期间比较了季节性变应性鼻炎的两种治疗策略。全科医生被随机分为两组。在第一组224例患者中,医生遵循《鼻炎国际共识》的指南。根据使用视觉模拟量表定义的鼻和眼症状的严重程度,患者接受依巴斯汀(一种口服抗组胺药)、曲安奈德(一种局部用皮质类固醇)和/或奈多罗米钠滴眼液(一种局部用眼部色酮)。在第二组241例患者中,全科医生可自由选择治疗方法。主要疗效终点是使用标准化的变应性鼻炎生活质量问卷(RQLQ)测量的生活质量以及每天通过电子日记系统评估的症状-药物评分。
指南策略组21天调整后的平均总症状评分为4.93,而自由选择治疗组为7.48(P = 0.0001)。指南组RQLQ的平均总分下降了2.19,而自由选择治疗组下降了1.79(P = 0.0001)。在21天时,指南组与自由选择治疗组相比,RQLQ总体评分改善的最小二乘平均差异为0.53,大于最小重要差异。
季节性变应性鼻炎患者常出现严重症状,医生使用自己的严重程度和治疗标准往往认识不足或控制不佳。通过使用一种简单的严重程度评估方法和基于国际指南的简单治疗方案,与接受非标准化治疗的患者相比,季节性变应性鼻炎患者有显著改善。